Phase III trial yields favorable results for pixantrone

03/23/2009 | RTT News

A Phase III trial showed that relapsed non-Hodgkin's lymphoma patients who received Cell Therapeutics' immunosuppressant drug pixantrone achieved a high rate of confirmed and unconfirmed remissions compared with those who received standard chemotherapy. The company is planning to file a new-drug application for pixantrone within the first half of the year.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care